CSIMarket Company Name, Ticker, Competitors, else..
 
Kuvatris Therapeutics Inc   (PXMD)
 

Kuvatris Therapeutics Inc's Suppliers Performance

PXMD's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
PXMD Costs vs Sales of Suppliers Growth

• More on PXMD Suppliers






Kuvatris Therapeutics Inc's Comment on Supply Chain


The company utilizes Contract Manufacturers (CMOs) and Contract Laboratories (CLOs) for the manufacturing and testing of critical intermediates and active pharmaceutical ingredients, including suramin. In 2019 and 2020, the company entered into multiple agreements with CMOs for the development and cGMP-compliant production of suramin to support clinical trials and future commercial supply of PAX-101. Bayer is currently the sole manufacturer of suramin, producing it irregularly and in limited quantities. The company has engaged two independent contract development manufacturing organizations to develop, validate, and scale the supply chain for suramin and its shelf-stable drug product. Production of suramin commenced in late 2023, with final development phases beginning in November 2023. The company continues to seek alternative manufacturing sources and partnerships to maintain an uninterrupted supply chain and adequate manufacturing capacity. All CMOs and CLOs are subject to audits to ensure compliance with cGMP and FDA Quality Systems requirements.

Kuvatris Therapeutics Inc's Comment on Supply Chain


The company utilizes Contract Manufacturers (CMOs) and Contract Laboratories (CLOs) for the manufacturing and testing of critical intermediates and active pharmaceutical ingredients, including suramin. In 2019 and 2020, the company entered into multiple agreements with CMOs for the development and cGMP-compliant production of suramin to support clinical trials and future commercial supply of PAX-101. Bayer is currently the sole manufacturer of suramin, producing it irregularly and in limited quantities. The company has engaged two independent contract development manufacturing organizations to develop, validate, and scale the supply chain for suramin and its shelf-stable drug product. Production of suramin commenced in late 2023, with final development phases beginning in November 2023. The company continues to seek alternative manufacturing sources and partnerships to maintain an uninterrupted supply chain and adequate manufacturing capacity. All CMOs and CLOs are subject to audits to ensure compliance with cGMP and FDA Quality Systems requirements.







PXMD's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Kuvatris Therapeutics Inc 0.00 0.00 -13.54 10
SUBTOTAL 0.00 0.00 0.00 -


Sources: Kuvatris Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Kuvatris Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.